Dr. Alexander Shulgin, an American chemist and pharmacologist, first produced 2C-B in 1974. It was introduced to therapists in the United States in the late 1970s. A German pharmaceutical company became the first to manufacture and sell the drug worldwide under the trade name Nexus. The company marketed Nexus as a treatment for impotency and frigidity. Several other foreign pharmaceutical companies followed suit, marketing the drug under the brand names of Eros and Performax. By 1993, the United States had become the largest market for 2C-B, which was being sold without the need for a prescription. Around the same time, researchers studying the emerging music and dance phenomena known as "raves" found 2C-B played a significant part in these activities. It was listed as a Schedule I drug by the DEA in 1995.